AUTHOR=Litvinova L. S. , Shupletsova V. V. , Khaziakhmatova O. G. , Daminova A. G. , Kudryavtseva V. L. , Yurova K. A. , Malashchenko V. V. , Todosenko N. M. , Popova V. , Litvinov R. I. , Korotkova E. I. , Sukhorukov G. B. , Gow A. J. , Weissman D. , Atochina-Vasserman E. N. , Khlusov I. A. TITLE=Human Mesenchymal Stem Cells as a Carrier for a Cell-Mediated Drug Delivery JOURNAL=Frontiers in Bioengineering and Biotechnology VOLUME=10 YEAR=2022 URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.796111 DOI=10.3389/fbioe.2022.796111 ISSN=2296-4185 ABSTRACT=
A number of preclinical and clinical studies have demonstrated the efficiency of mesenchymal stromal cells to serve as an excellent base for a cell-mediated drug delivery system. Cell-based targeted drug delivery has received much attention as a system to facilitate the uptake a nd transfer of active substances to specific organs and tissues with high efficiency. Human mesenchymal stem cells (MSCs) are attracting increased interest as a promising tool for cell-based therapy due to their high proliferative capacity, multi-potency, and anti-inflammatory and immunomodulatory properties. In particular, these cells are potentially suitable for use as encapsulated drug transporters to sites of inflammation. Here, we studied the